aDeganit Barak-Shinar, PhD; bRuben del Río, MD; cLawrence J. Green, MD aaKamedis Ltd., Tel-Aviv, Israel bEsperit Sant Hospital of Santa Coloma de Gramenet, Barcelona, Spain cGeorge Washington University School of Medicine, Washington, D.C. Disclosure: Dr. Barak-Shinar is an employee of Kamedis Ltd., the manufacturer of Seborrheamedis Face Cream and the sponsor of this study. Dr.
aIsabelle Rousseaux, MD; bSam Robson, MRCGP aCabinet de Dermatologie Esthétique, Lille Côté Sud, Loos, France; bTemple Medical, Aberdeen, United Kingdom Disclosure: The authors report no relevant conflicts of interest. Abstract Objective: The objective of this study was to examine the efficacy and safety of the latest multisource radiofrequency handpiece, specially designed for body area skin
Metavee Boonsiri, MD; DeAnna Diaz, MS; Theerayuth Sukmee, MD; Joyce Okawa, RN; Chérie M. Ditre, MD Cosmetic Enhancement Center, Penn Medicine Radnor, University of Pennsylvania, Radnor, Pennsylvania Disclosure: The authors report no relevant conflicts of interest. Abstract Objective: The purpose of this study was to compare the use of benzocaine, lidocaine, tetracaine (BLT) cream with
aAmanda F. Nahhas, DO; aChase A. Scarbrough, DO; bShannon Trotter, DO aOhioHealth O’Bleness Hospital, Athens, Ohio bOhio State University Wexner Medical Center, Columbus, Ohio Disclosure: The authors report no relevant conflicts of interest. Abstract Background: Adequate treatment and follow-up of a patient with nonmelanoma skin cancer is of utmost concern for a clinician. However, there
aXinyi Yang, BMed/MD; bMatthew S. Dinehart, BA, MEd aThe Royal Prince Alfred Hospital, Camperdown, NSW, Australia aUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas Disclosure: The authors report no relevant conflicts of interest. Abstract Vismodegib, a potent inhibitor of the hedgehog pathway, is an effective treatment for advanced basal cell carcinoma. More recently, it